Anti-IL-17 a New Treatment for Contact Dermatititis
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of anti-IL 17 treatment (secukinumab) in
patients with known severe allergic contact dermatitis (ACD).